天智航(688277.SH):擬定增募資不超13.4億元 用於骨科手術機器人研發及產業化項目等
格隆匯6月23日丨天智航(688277.SH)公吿,本次向特定對象發行股票的數量按照募集資金總額除以發行價格確定,且不超過本次發行前公司總股本的15%,即本次發行不超過6297.7027萬股(含)。本次向特定對象發行股票的發行價格為不低於定價基準日前二十個交易日公司股票交易均價的80%。
本次向特定對象發行股票募資總額不超過人民幣13.4億元(含),扣除相關發行費用後,擬將6.622億元用於新一代骨科手術機器人研發及產業化項目,將3.128億元用於營銷體系升級項目,將2.15億元用於智慧醫療中心建設項目,將1.5億元用於科技儲備資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.